Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).
Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).
复制标题
分离的 t(6;9)(p23;q34) 骨髓肿瘤的临床病理学和分子特征。
DOI：
10.1111/ijlh.12641
复制
发表时间：
2017
影响因子：
3
通讯作者：
Rogers,HJ
中科院分区：
文献类型：
--
作者：
Visconte,V;Shetty,S;Przychodzen,B;Hirsch,C;Bodo,J;Maciejewski,JP;Hsi,ED;Rogers,HJ
IntroductionThe t(6;9)(p23;q34);DEK‐NUP214 [t(6;9)] abnormality is found in 0.7–1.8% of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).FLT3‐ITD mutations are detected in t(6;9) patients. The t(6;9) abnormality is associated with poor outcomes. We studied the clinicopathologic and molecular profiles of patients with AML/MDS carrying t(6;9).MethodsWe collected clinical data of nine patients with AML/MDS with isolated t(6;9) (median age = 41 years; male/female = 4/5) and genotyped DNAs using whole exome, Sanger, and targeted sequencing.ResultsOur cohort was characterized by frequent multilineage dysplasia (56%), absence of phospho‐STAT3/STAT5 expression, presence of myeloid markers (CD13, CD33, CD34, CD117, HLA‐DR) with an aberrant expression of CD7, and poor outcome (median survival of 20 months). Although basophilia has been described in association with t(6;9), we observed lack of marrow basophilia in our cohort. Molecularly, 83% (5/6) of patients with AML/MDS with t(6;9) were characterized by at least one somatic mutation. Among them, four patients showed multiple mutations.FLT3‐ITD mutations were detected in 33% of patients (2/6); 80% (4/5) of mutant patients died even after hematopoietic stem cell transplantation.ConclusionOur data demonstrated that AML/MDS patients with t(6;9) have diverse molecular mutations regardless of the presence ofFLT3 mutations, which may contribute to their poor survival outcomes.
